Weill Cornell Medicine and Columbia University Medical Center, in collaboration with NewYork-Presbyterian and NYC Health + Hospitals/Harlem, have been awarded a grant from the NIH worth $4 million in the first year of funding to improve physicians' ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics. The grant, which could total $46.5 million over five years, will enable researchers to enroll patients in the Cohort Program of President Barack Obama's Precision Medicine Initiative (PMI) in order to better understand the genetic and other biological drivers of disease, and how they relate to overall health.
Mark A Rubin, MD
Director, Institute for Precision Medicine
Precision medicine, an emerging approach for disease treatment and prevention, takes into account individual variability in genes, environment and lifestyle for each person. Columbia and Weill Cornell Medicine, along with several other medical centers and institutions across the country, will provide expertise and infrastructure to launch the PMI Cohort Program. This landmark research program aims to engage 1 million or more diverse U.S. volunteers in an effort to extend the success of precision medicine in some cancers to many other diseases. Importantly, the program will also focus on ways to increase a person's chances of remaining healthy throughout life.